The School of Dentistry University of Birmingham
Birmingham, B4 6NN, United Kingdom
NCT Number: NCT01706588
This is a prospective, randomised, double-blind, placebo-controlled, parallel group study in approximately 75 patients undergoing surgical removal of an impacted lower third molar.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 2
Birmingham, B4 6NN, United Kingdom
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
General
One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
Other names: Diclofenac HPBCD
Time frame: Pain scores will be measured over the time from end of surgery (time 0) to the 6 hour post-surgery
Pain will be scored by the patient at the end of surgery (time 0) and at 15-minute intervals after surgery for a total of 6 hours on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).
Time frame: measured at 6 hours postsurgery, at day 3 and 1 week postsurgery
Time frame: measured at 6 hours postsurgery, at day 3 and 1 week postsurgery
Time frame: measured from end of surgery up to 12 hours postsurgery
Time frame: measured from end of surgery up to 1 week postsurgery
Time frame: consumed by the patient every 15-minutes postsurgery up to 6 hours postsurgery
Time frame: consumed by the patient from end of surgery up to 24 and up to 48 hours postsurgery
Time frame: at 6 hour postsurgery and on Day 3
Time frame: measured from end of surgery up to 12 hours postsurgery
Time frame: at 6 hour postsurgery, and on day 3 and 1 week postsurgery
Time frame: every hour up to 6 hour postsurgery
Time frame: presurgery (within 30 days from surgery), at day of surgery (day 1), day 3 and 1 week postsurgery.
Time frame: from signature of the informed consent to 1 week postsurgery
IBSA Institut Biochimique SA
Industry
Preliminary Evaluation of the Efficacy and Local Tolerability of Injectable Diclofenac at 5, 12.5, 25 and 50 mg/mL, Administered Locally Prior to Surgery for the Prevention of Post-operative Pain After Third Molar Surgery
Acronym: DP4
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05283980
Acute Pain, Behavior
Boston, Massachusetts, United States
View Trial DetailsNCT02417337
Irreversible Pulpitis, Neurologic Manifestations
Khartoum, Sudan
View Trial DetailsNCT05738239
Neurologic Manifestations, Pain
Hamilton, Ontario, Canada
View Trial DetailsNCT07533760
Abdominal Hysterectomy, Neurologic Manifestations
Konya, Turkey (Türkiye)
View Trial Details